8legs: European union, european union

#1 out of 1

Lenivia Approval Might Change The Case For Investing In Zoetis (ZTS)

The European Commission granted marketing authorization for Lenivia in dogs, extending Zoetis's pain-management portfolio.
Lenivia’s longer duration and novel binding set it apart from existing osteoarthritis therapies.
The approval aligns with Zoetis's strategy to grow long-acting biologics and expand addressable markets.
Portela (relfove) in Europe for cats is noted as a related recent launch in the portfolio.
Analysts expect Lenivia to influence long-term growth and margins if adoption is strong.
Zoetis projects significant revenue and earnings growth by 2028 based on ongoing innovation.
Some community estimates vary, with members placing fair value estimates between US$153 and US$230.
The article notes risk factors include adoption speed and safety considerations for OA pain products.
Zoetis emphasizes a focus on long-acting biologics to sustain growth.
The piece underscores the broader market context, including other animal health launches.

Vote 0